Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6QDH

Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000906

Summary for 6QDH
Entry DOI10.2210/pdb6qdh/pdb
Related4CGO
DescriptorGlycylpeptide N-tetradecanoyltransferase, TETRADECANOYL-COA, 4-[ethyl(methyl)amino]-2-[methyl-(1-methylpiperidin-4-yl)amino]-~{N}-(1,3,5-trimethylpyrazol-4-yl)quinazoline-6-sulfonamide, ... (7 entities in total)
Functional Keywordstransferase, myristoylation, quinazoline, leishmania
Biological sourceLeishmania major
Total number of polymer chains1
Total formula weight50590.80
Authors
Brannigan, J.A. (deposition date: 2019-01-01, release date: 2020-05-06, Last modification date: 2024-01-24)
Primary citationBell, A.S.,Yu, Z.,Hutton, J.A.,Wright, M.H.,Brannigan, J.A.,Paape, D.,Roberts, S.M.,Sutherell, C.L.,Ritzefeld, M.,Wilkinson, A.J.,Smith, D.F.,Leatherbarrow, R.J.,Tate, E.W.
Novel Thienopyrimidine Inhibitors of Leishmania N -Myristoyltransferase with On-Target Activity in Intracellular Amastigotes.
J.Med.Chem., 63:7740-7765, 2020
Cited by
PubMed Abstract: The leishmaniases, caused by species of protozoan parasites, are neglected tropical diseases with millions of cases worldwide. Current therapeutic approaches are limited by toxicity, resistance, and cost. -Myristoyltransferase (NMT), an enzyme ubiquitous and essential in all eukaryotes, has been validated via genetic and pharmacological methods as a promising anti-leishmanial target. Here we describe a comprehensive structure-activity relationship (SAR) study of a thienopyrimidine series previously identified in a high-throughput screen against NMT, across 68 compounds in enzyme- and cell-based assay formats. Using a chemical tagging target engagement biomarker assay, we identify the first inhibitor in this series with on-target NMT activity in leishmania parasites. Furthermore, crystal structure analyses of 12 derivatives in complex with NMT revealed key factors important for future structure-guided optimization delivering IMP-105 (), a compound with modest activity against intracellular amastigotes and excellent selectivity (>660-fold) for NMT over human NMTs.
PubMed: 32575985
DOI: 10.1021/acs.jmedchem.0c00570
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.45 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon